About: Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Creator	Liu, Jing Xiong, Nian Peng, Ling Zhang, Tao Li, Jun Jin, Yang Peng, L Jiang, Ke Huang, Yu Huang, Chaolin Li, Yuhui Huang, Y Liu, J Wu, G Yang, Yang, J Zhang, R Li, G Wei, J Cai, Liqiong Dong, Youhong Li, Guiling Lu, Hongda Pan, Dongfeng Sheng, Y Sheng, Yuhan Shu, Chengrong Wei, Jielin Wu, Bian Wu, Gang Wu, Mengjiao Wu, M Yang, Jiyuan Yang, Kunyu Zhang, Ruiguang Zhang, T
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Patients with cancer are a high-risk population in the COVID-19 pandemic. We aimed to describe clinical characteristics and outcomes of patients with cancer and COVID-19, and examined risk factors for mortality in this population. METHODS: We did a retrospective, multicentre, cohort study of 205 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and with a pathological diagnosis of a malignant tumour in nine hospitals within Hubei, China, from Jan 13 to March 18, 2020. All patients were either discharged from hospitals or had died by April 20, 2020. Clinical characteristics, laboratory data, and cancer histories were compared between survivors and non-survivors by use of χ(2) test. Risk factors for mortality were identified by univariable and multivariable logistic regression models. FINDINGS: Between Jan 13 and Mar 18, 2020, 205 patients with cancer and laboratory-confirmed SARS-CoV-2 infection were enrolled (median age 63 years [IQR 56–70; range 14–96]; 109 [53%] women). 183 (89%) had solid tumours and 22 (11%) had haematological malignancies. The median duration of follow-up was 68 days (IQR 59–78). The most common solid tumour types were breast (40 [20%] patients), colorectal (28 [14%]), and lung cancer (24 [12%]). 54 (30%) of 182 patients received antitumour therapies within 4 weeks before symptom onset. 30 (15%) of 205 patients were transferred to an intensive care unit and 40 (20%) died during hospital admission. Patients with haematological malignancies had poorer prognoses than did those with solid tumours: nine (41%) of 22 patients with haematological malignancies died versus 31 (17%) of 183 patients with solid tumours (hazard ratio for death 3·28 [95% CI 1·56–6·91]; log rank p=0·0009). Multivariable regression analysis showed that receiving chemotherapy within 4 weeks before symptom onset (odds ratio [OR] 3·51 [95% CI 1·16–10·59]; p=0·026) and male sex (OR 3·86 [95% CI 1·57–9·50]; p=0·0033) were risk factors for death during admission to hospital. INTERPRETATION: Patients with cancer and COVID-19 who were admitted to hospital had a high case-fatality rate. Unfavourable prognostic factors, including receiving chemotherapy within 4 weeks before symptom onset and male sex, might help clinicians to identify patients at high risk of fatal outcomes. FUNDING: National Natural Science Foundation of China.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1016/s1470-2045(20)30310-7
bibo:pmid	32479787
has license	no-cc
sha1sum (hex)	161b515f16a7b5cdf35d84470c37ac73d9fb5468
schema:url	https://doi.org/10.1016/s1470-2045%2820%2930310-7
resource representing a document's title	Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
has PubMed Central identifier	PMC7259917
has PubMed identifier	32479787
schema:publication	Lancet Oncol
resource representing a document's body	covid:161b515f16a7b5cdf35d84470c37ac73d9fb5468#body_text
is schema:about of	named entity 'risk factors' named entity 'COVID-19' named entity 'Patients' named entity 'chemotherapy' named entity 'lymphopenia' named entity 'side-effects' named entity 'interferon-γ' named entity 'China' named entity 'Clinical' named entity 'COVID-19' named entity 'Clinical characteristics' named entity 'China' named entity 'C-reactive protein' named entity 'Middle East respiratory syndrome coronavirus' named entity 'SARS-CoV-2' named entity 'regression model' named entity 'case-fatality rates' named entity 'Lower respiratory tract' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'neutrophils' named entity 'antiviral medications' named entity 'benign tumour' named entity 'oral administration' named entity 'type I error' named entity 'Hubei' named entity 'Invasive mechanical ventilation' named entity 'infection' named entity 'immune system function' named entity 'COVID' named entity 'mechanical ventilation' named entity 'symptom' named entity 'COVID' named entity 'solid tumours' named entity 'procalcitonin' named entity 'creatine kinase' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'chemotherapy' named entity 'oxygen therapy' named entity 'cervical cancer' named entity 'prognoses' named entity 'lung' named entity 'case-fatality rates'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software